Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
specific nucleic acid SNA-HLA I
- Development stage
- Unknown
- Lead developer
- Labo'Life
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Sublingual
01
Overview
Specific nucleic acid SNA-HLA I is a therapeutic component utilized in micro-immunotherapy, a medical approach developed by Labo'Life. It consists of synthetic nucleic acids (DNA or RNA) prepared at ultra-low doses, designed to regulate the immune system's response to viral pathogens. Specifically, SNA-HLA I is intended to modulate the expression and function of Human Leukocyte Antigen (HLA) Class I molecules. HLA Class I proteins are critical for the presentation of intracellular viral antigens to CD8+ cytotoxic T lymphocytes, which are the primary effectors in the elimination of virally infected cells. By optimizing this antigen presentation pathway, SNA-HLA I aims to enhance the body's natural defense mechanisms against the Herpes Simplex Virus (HSV), thereby reducing the frequency, duration, and severity of orofacial herpes outbreaks and other HSV-related infections. It is typically administered sublingually as part of a complex micro-immunotherapy formulation.
- Other names
- SNA-HLA-ISpecific Nucleic Acid HLA I
02
Targets
MHC I (MHC class I})
Beyond the preview
Go deeper on specific nucleic acid SNA-HLA I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on specific nucleic acid SNA-HLA I.